Literature DB >> 18094139

Molecular epidemiology of extended-spectrum beta-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006.

Hong Fang1, Ferda Ataker, Göran Hedin, Kathrine Dornbusch.   

Abstract

The genetic characteristics and molecular epidemiology of extended-spectrum beta-lactamases (ESBLs) among Escherichia coli isolates were investigated at a general hospital and its associated health care facilities in Stockholm, Sweden, during the period from 2001 to 2006. Of 87 consecutive nonduplicate ESBL-positive isolates, 80 isolates encoded CTX-M-type ESBLs, 64 of which were group 1 enzymes. TEM-type and OXA-type beta-lactamases were encoded in 63 and 59% of the ESBL isolates, respectively. Pulsed-field gel electrophoresis (PFGE) analysis revealed 40 different pulsotypes, consisting of 11 clones accounting for 66% of all isolates, and 29 unique patterns. Moreover, of the 11 clones, clones 1 and 4 comprised half of the clonally related isolates (28 of 57). Clone 1 was a persistent endemic clone in the area throughout the years, and clone 4 emerged in 2003. However, in recent years, clone 1 isolates were no longer predominant and were gradually replaced by new emerging strains. Concerning beta-lactamase gene profiles in relation to PFGE pulsotypes, clone-related bla profiles were observed in certain clones, while in most cases different bla profiles could be observed in the same clone, and the same bla profile could be present in different clones. The molecular epidemiology of ESBL-positive E. coli in the area shows shifts in predominant strains and increased clonal diversity over time. The study also indicated that both clonal spread of epidemic strains and transfer of transposable genetic elements might contribute to the proliferation of ESBLs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18094139      PMCID: PMC2238137          DOI: 10.1128/JCM.01943-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  Molecular epidemiological analysis of Escherichia coli isolates producing extended-spectrum beta-lactamases for identification of nosocomial outbreaks in Stockholm, Sweden.

Authors:  Hong Fang; Christina Lundberg; Barbro Olsson-Liljequist; Göran Hedin; Emma Lindbäck; Asa Rosenberg; Johan Struwe
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

2.  Widely distributed and predominant CTX-M extended-spectrum beta-lactamases in Amsterdam, The Netherlands.

Authors:  N al Naiemi; A Bart; M D de Jong; C M Vandenbroucke-Grauls; P J G M Rietra; Y J Debets-Ossenkopp; P C Wever; L Spanjaard; A J Bos; B Duim
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

Review 3.  The CTX-M beta-lactamase pandemic.

Authors:  Rafael Cantón; Teresa M Coque
Journal:  Curr Opin Microbiol       Date:  2006-08-30       Impact factor: 7.934

4.  Emergence of Enterobacteriaceae isolates producing CTX-M extended-spectrum beta-lactamase in Austria.

Authors:  Alexandra Eisner; Elizabeth J Fagan; Gebhard Feierl; Harald H Kessler; Egon Marth; David M Livermore; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 5.  Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases.

Authors:  Michael A Pfaller; John Segreti
Journal:  Clin Infect Dis       Date:  2006-04-15       Impact factor: 9.079

6.  Precise insertion of antibiotic resistance determinants into Tn21-like transposons: nucleotide sequence of the OXA-1 beta-lactamase gene.

Authors:  M Ouellette; L Bissonnette; P H Roy
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

Review 7.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

Review 8.  Extended-spectrum beta-lactamases in Taiwan: epidemiology, detection, treatment and infection control.

Authors:  Wen-Liang Yu; Yin-Ching Chuang; Jan Walther-Rasmussen
Journal:  J Microbiol Immunol Infect       Date:  2006-08       Impact factor: 4.399

Review 9.  Application of molecular techniques to the study of hospital infection.

Authors:  Aparajita Singh; Richard V Goering; Shabbir Simjee; Steven L Foley; Marcus J Zervos
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

10.  Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK.

Authors:  N Woodford; M E Ward; M E Kaufmann; J Turton; E J Fagan; D James; A P Johnson; R Pike; M Warner; T Cheasty; A Pearson; S Harry; J B Leach; A Loughrey; J A Lowes; R E Warren; D M Livermore
Journal:  J Antimicrob Chemother       Date:  2004-09-03       Impact factor: 5.790

View more
  41 in total

1.  Prospective study of fecal colonization by extended-spectrum-beta-lactamase-producing Escherichia coli in neutropenic patients with cancer.

Authors:  L Calatayud; M Arnan; J Liñares; M A Dominguez; C Gudiol; J Carratalà; M Batlle; J M Ribera; F Gudiol
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

2.  Characteristics of carbapenemase-producing Klebsiella pneumoniae as a cause of neonatal infection in Shandong, China.

Authors:  Yan Jin; Xiaofei Song; Yigang Liu; Yong Wang; Bingchang Zhang; Hui Fan; Chunhong Shao
Journal:  Exp Ther Med       Date:  2017-01-20       Impact factor: 2.447

3.  Frequent occurrence of extended-spectrum beta-lactamase- and transferable ampc beta-lactamase-producing Escherichia coli on domestic chicken meat in Sweden.

Authors:  Stefan Börjesson; Maria Egervärn; Mats Lindblad; Stina Englund
Journal:  Appl Environ Microbiol       Date:  2013-01-25       Impact factor: 4.792

4.  Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies.

Authors:  M Arnan; C Gudiol; L Calatayud; J Liñares; M Á Dominguez; M Batlle; J M Ribera; J Carratalà; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-10-30       Impact factor: 3.267

5.  High rate of fecal carriage of extended-spectrum-β-lactamase-producing Escherichia coli in healthy children in Gipuzkoa, northern Spain.

Authors:  María Fernández-Reyes; Diego Vicente; María Gomariz; Olatz Esnal; Joseba Landa; Eider Oñate; Emilio Pérez-Trallero
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

6.  Molecular identification of extended-spectrum-β-lactamase genes from Enterobacteriaceae isolated from healthy human carriers in Switzerland.

Authors:  Nadine Geser; Roger Stephan; Bozena M Korczak; Lothar Beutin; Herbert Hächler
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

7.  In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli.

Authors:  M Tärnberg; A Ostholm-Balkhed; H-J Monstein; A Hällgren; H Hanberger; L E Nilsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-02-06       Impact factor: 3.267

Review 8.  Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices.

Authors:  Johann D D Pitout
Journal:  Drugs       Date:  2010-02-12       Impact factor: 9.546

9.  Clinico-microbiological study and antibiotic resistance profile of mecA and ESBL gene prevalence in patients with diabetic foot infections.

Authors:  Waqas Nasir Chaudhry; Rabia Badar; Muhsin Jamal; Jason Jeong; Jamal Zafar; Saadia Andleeb
Journal:  Exp Ther Med       Date:  2016-01-14       Impact factor: 2.447

10.  Molecular characterization of multidrug resistant hospital isolates using the antimicrobial resistance determinant microarray.

Authors:  Tomasz A Leski; Gary J Vora; Brian R Barrows; Guillermo Pimentel; Brent L House; Matilda Nicklasson; Momtaz Wasfy; Mohamed Abdel-Maksoud; Chris Rowe Taitt
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.